The 36-month beta value for ATOS is at 1.24. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATOS is 125.25M, and currently, shorts hold a 9.86% of that float. The average trading volume for ATOS on May 02, 2024 was 1.75M shares.
ATOS) stock’s latest price update
Atossa Therapeutics Inc (NASDAQ: ATOS)’s stock price has plunge by 0.98relation to previous closing price of 1.53. Nevertheless, the company has seen a 1.64% surge in its stock price over the last five trading sessions. Proactive Investors reported 2024-04-15 that Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating Atossa’s lead drug candidate (Z)-endoxifen in combination with Eli Lilly and Co (NYSE:LLY)’s abemaciclib (VERZENIO) in women with Estrogen Receptor positive (ER+)/Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. The clinical-stage biopharmaceutical company said the new study arm would enroll approximately 20 women newly diagnosed with ER+/HER2- invasive breast cancer.
ATOS’s Market Performance
Atossa Therapeutics Inc (ATOS) has seen a 1.64% rise in stock performance for the week, with a -23.70% decline in the past month and a 84.02% surge in the past quarter. The volatility ratio for the week is 6.09%, and the volatility levels for the past 30 days are at 11.92% for ATOS. The simple moving average for the past 20 days is -3.92% for ATOS’s stock, with a 56.72% simple moving average for the past 200 days.
Analysts’ Opinion of ATOS
Many brokerage firms have already submitted their reports for ATOS stocks, with Maxim Group repeating the rating for ATOS by listing it as a “Buy.” The predicted price for ATOS in the upcoming period, according to Maxim Group is $2 based on the research report published on January 26, 2018 of the previous year 2018.
ATOS Trading at 6.11% from the 50-Day Moving Average
After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.12% of loss for the given period.
Volatility was left at 11.92%, however, over the last 30 days, the volatility rate increased by 6.09%, as shares sank -27.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +50.50% upper at present.
During the last 5 trading sessions, ATOS remain unchanged, which changed the moving average for the period of 200-days by +33.33% in comparison to the 20-day moving average, which settled at $1.5790. In addition, Atossa Therapeutics Inc saw 75.57% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATOS starting from Finn Jonathan, who purchase 25,000 shares at the price of $1.77 back on Apr 10 ’24. After this action, Finn Jonathan now owns 25,000 shares of Atossa Therapeutics Inc, valued at $44,250 using the latest closing price.
WEAVER GREGORY L, the Former EVP, CFO, & Director of Atossa Therapeutics Inc, sale 50,000 shares at $0.65 during a trade that took place back on Nov 15 ’23, which means that WEAVER GREGORY L is holding 55 shares at $32,500 based on the most recent closing price.
Stock Fundamentals for ATOS
The total capital return value is set at -0.34. Equity return is now at value -28.80, with -27.38 for asset returns.
Currently, EBITDA for the company is -31.35 million with net debt to EBITDA at 3.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.61.
Conclusion
In conclusion, Atossa Therapeutics Inc (ATOS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
